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1. Introduction
   Diabetes mellitus (DM) is a concerning health problem 
for the Asia Pacific region where late diagnosis and poor 
monitoring is associated with increased risk of microvascular 
and macrovascular disease, disability and mortality often 
prematurely[1-3]. Recently, the Australian diabetes, obesity 
and lifestyle study indicated that in a national sample of 
those aged greater than 25 years old, there was an overall 
DM prevalence of 7.5%, with an estimated 50% of these cases 
being previously undiagnosed[4]. The importance of early 
and accurate diagnosis has been proven to significantly 
reduce the risk of unwanted complications as demonstrated 
by the United Kingdom prospective diabetes study[5]. Prior 
to 2010, blood glucose analysis has been the exclusive and 
gold standard method to diagnose T2DM. However, recently 
the World Health Organization (WHO) and the International 
Diabetes Federation has recommended hemoglobin A1C 
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(HbA1C) as a diagnostic test[6]. Although it is not currently 
recommended in all but one of the Asia Pacific countries, 
many physicians globally have taken a liking to HbA1C and 
this newfound use. Historically, HbA1C has previously only 
been utilized to monitor glycemic control and guide therapy 
in those already diagnosed[5,7]. With a strong correlation able 
to be made between HbA1C and retinopathy, as well as other 
microvascular complications, the convenience of sampling 
HbA1C at any time without regard to food ingestion removes 
the methodological, procedural and practical problems of 
measuring blood glucose levels[7,8]. This report will further 
discuss the concepts behind HbA1C and the scientific method 
of its application, the advancement and validity in its 
practical implementation, its limits, as well as its usefulness 
in the detection of millions of people who would otherwise 
be left undiagnosed, particularly in rural and remote regions 
of the Asia Pacific.
2. Hemoglobin A1C in clinical practice
2.1. Biochemical basis of HbA1C 
   The discovery of HbA1C and its association with blood 
glucose measurements have been rigorously investigated 
since the 1960s. Rahbar initially identified HbA1C as an 
“unusual hemoglobin in patients with diabetes”[9]. However, 
at the same time, despite there being a strong suspicion that 
hyperglycemia was associated with vascular complications, 
it was difficult to prove without an objective marker of 
glucose control[7]. With this purpose and need for a marker 
in mind, throughout the following two decades, multiple 
studies were conducted to find the correlation between HbA1C 
and glucose measurements. It became widely published that 
HbA1C was the hemoglobin component of an erythrocyte that 
was composed of glycohemoglobin[9]. With the erythrocyte 
cell membrane being highly permeable, hemoglobin was 
easily exposed to intracellular levels of glucose. During these 
occasions, via nonenzymatic attachment, glucose bound to 
the N-terminal valine on the β chain of hemoglobin, forming 
HbA1C[10]. With the attachment of glucose to the hemoglobin 
remaining there for the lifetime of the erythrocyte, it became 
apparent that the amount of HbA1C that was formed would 
reflect the level of glucose exposure. As the life span of an 
erythrocyte on average is approximately 120 d, blood sample 
at any given time would include erythrocytes of different 
ages with varying degrees of exposure to glucose[10]. Despite 
elder erythrocytes being exposed to more hyperglycemia, 
younger erythrocytes are more prominent in a blood sample. 
With approximately 50% of HbA1C representing blood glucose 
levels over the preceding 30 d, and 10% the previous 90-
120 d, the measured HbA1C was able to be extrapolated 
to provide an estimation of average glucose control over 
the past 2-3 months[10]. The method selected to measure 
HbA1C is dependent on the laboratory, with approximately 
100 different ways of doing so. The use of antibodies in 
immunoassays and cation-exchange chromatography are 
two methods most widely used to efficiently separate the 
glycated from the non-glycated hemoglobin[7]. Regression 
equations, developed using data from earlier studies, are 
then used to generate average blood glucose levels from 
HbA1C, ultimately aiding in the development of current DM 
management guidelines[7].
2.2. Application and validity of HbA1C
   By the 1980s, the association between glucose control 
and HbA1C and development of diabetic complications 
was evident, supporting the implementation of HbA1C to 
the clinical environment; a recognizable cornerstone in 
clinical practice[4]. Two studies, the Diabetes Control and 
Complications Trial and the UK Prospective Diabetes Study, 
cleverly illustrated that in both type 1 diabetes mellitus 
(T1DM) and T2DM, intensive blood glucose control, obvious 
in blood glucose and HbA1C measurements, decreased 
the risk of microvascular complications[10]. Both studies 
also demonstrated how the HbA1C result can allow the 
establishment of specific treatment goals; appropriate 
lifestyle and medication adjustment[10]. On the basis of the 
results from these trials, DM organizations globally began 
and currently still use HbA1C as a significant tool to monitor 
glucose control and guide management[6]. The current 
Australian DM guideline outlines that the general HbA1C target 
in people with T2DM is less or equal to 7%[8]. A result greater 
than 7% in those without severe hypoglycemia, limited life 
expectancy, or co-morbidities and who isn’t elderly, should 
prompt more active hypoglycemic treatment as suggested 
by the International Diabetes Federation[6]. It is further 
recommended that both those patients with T1DM or T2DM 
have their HbA1C tested every 3-6 months[10,11]. Although 
target levels are specified and provide ranges to guide point 
of intervention, most importantly, as the guidelines state, 
any significant reduction in HbA1C will improve patient 
outcomes; with each 1% reduction resulting in a 20% to 40% 
decrease in risk of developing complications[4].
2.3 Advances in the utilization of HbA1C
   To reduce the risk of impact of T2DM, both micro and 
macrovascular complications, early diagnosis is recognized 
as the ultimate solution[8]. However, for the presence or 
absence of a chronic disease to be determined, a diagnostic 
tool must have a low degree of intra-individual variation[7]. 
With the fasting plasma glucose and oral glucose tolerance 
tests both performing poorly on this measure, further use 
of HbA1C as a diagnostic tool has been pondered for the 
past decade. In 1997, expert committee on the diagnosis 
and classification of DM and another group in 2003 failed to 
recommend the use of HbA1C in the diagnosis of T2DM due to 
lack of standardization and no consensus on an appropriate 
cut-off point for DM identification[7]. In 2009 however, 
another international expert committee examined data on 
retinopathy prevalence and glycemic measures from nine 
countries and determined that HbA1C of 6.5% recognizes the 
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cut-point at which retinopathy begins to occur[6,7]. This 
finding, together with almost universal standardization 
o f  HbA 1C measurement  as  a  resul t  o f  a  Nat ional 
Glycohemoglobin Standardization Program, has encouraged 
the recommendation for HbA1C to be used to diagnose 
T2DM[8,12]. To date, the American Diabetes Association added 
HbA1C into its 2010 clinical practice recommendations with a 
cut-off value of 6.5% or greater alongside the glucose based 
criteria[3]. Although New Zealand adopted its use[13], other 
countries in the Asia Pacific region have yet to add HbA1C as 
a diagnostic tool, but as stated in 2012 Australian guidelines 
for diabetes management in general practice, it is a policy 
that maybe adopted in the future[4,8]. In Australia to date, 
Medicare does not fund HbA1C as a diagnostic or screening 
test for diabetes, only recognizing its use for those previously 
diagnosed, and further requiring evidence of such on the 
request form[3]. A systematic review conducted by WHO, 
compared fasting plasma glucose and HbA1C with the 10-
year incidence of retinopathy. It revealed that HbA1C of 6.5% 
had a positive predictive value of 15.9%, negative predictive 
value of 97%, a sensitivity of 7.9% and a specificity of 97%[14]. 
Therefore, this indicates that as a diagnostic test, when a 
positive diagnosis is made, it is highly likely to be correct. 
When practical considerations are considered alongside this 
finding, such as not requiring the patient to fast or undergo 
special preparation, allowing more convenient opportunistic 
screening in the usual clinic setting, and results not being 
influenced by short term stressors such as hospitalization 
and acute illness, it seems logical that this advancement in 
the utilization of HbA1C as a diagnostic tool should be pursued 
sooner rather than later within the Asia Pacific region[15].
2.4. Practical implementation of HbA1C as a diagnostic tool 
in remote areas
   With an increasing trend of reported T2DM in remote and 
rural areas of the Asia Pacific region, it is obvious that a 
diagnostic and monitoring solution that is opportunistic 
and allows immediate and easily interpretable results is 
necessary[1,15]. For instance, HbA1C in the form of point of 
care (POC), testing in Australia’s rural and remote Aboriginal 
and Torres Strait Islander communities seems ideal given 
the high specificity of the test and recognizing the largely 
nomadic nature of these communities. A study conducted 
in a remote aboriginal community in Australia, assessed 
and compared the accuracy of POC measurements of 
capillary blood glucose and HbA1C levels. At the conclusion 
of the study, they found that POC capillary HbA1C testing 
offered an accurate, practical, community-friendly way of 
monitoring DM, and illustrated how incorporating HbA1C as a 
diagnostic tool in these communities would be beneficial[16]. 
The precision of HbA1C testing was less than 3%, allowing 
clinically significant changes in serial HbA1C concentrations 
to be detected. These positive findings were compared to 
POC capillary glucose testing where conclusions at the end 
of the study recommended that results be confirmed by 
a laboratory test of venous plasma if they were likely to 
significantly influence clinical decisions. This is due to POC 
and laboratory results for glucose concentration showing 
a concentration-dependent difference[16]. These findings 
are particularly relevant when considering the distance 
between clinical settings and the laboratory in rural and 
remote communities. The distance patients often have to 
travel to access health care when there is uncertainty as to 
whether the patient has fasted, and when often dealing with 
a population where health is not a major priority. Hence, 
inclusion of HbA1C in the Australian guidelines outlining the 
diagnostic criteria for T2DM seems practical in the future, 
and even more so in rural and remote regions of the Asia 
Pacific, where early, accurate and on the spot diagnosis is 
essential[1,2].
2.5. Cost effectiveness of HbA1C as a diagnostic tool
   In order to improve population health in the Asia Pacific 
region where diabetes has reached epidemic proportion, 
replacement of a cost ineffective intervention to a cost-
effective one is often necessary[5]. Hence, before the 
implementation of HbA1C as a diagnostic tool, various 
countries performed a cost effective analysis to ensure the 
highest possible overall level of population health. Using 
population-based data, a study conducted in Germany 
compared the cost effectiveness of HbA1C, oral glucose 
tolerance test (OGTT) and fasting plasma glucose tests in the 
diagnosis of those with T2DM. It concluded that the most 
cost-effective diagnostic strategy was HbA1C combined with 
OGTT. Although costs were lower when attempting diagnosis 
with fasting plasma glucose combined with OGTT or OGTT 
alone, these tests detected only about one-third to one-
fourth of subjects with previously undiagnosed diabetes[17]. 
No cost effective analysis has been conducted in Australia 
to date with regards to HbA1C and the diagnosis of T2DM. 
However, in 2012, the Australian Diabetes Society and the 
Royal College of Pathologists of Australasia applied for an 
analytic protocol that will be used to guide the assessment 
of the safety, effectiveness and cost-effectiveness of HbA1C in 
making the diagnosis of T2DM and a listing on the Medicare 
Benefits Schedule[5]. This analysis is still pending. However, 
it is interesting to note some of the cost effective proposals 
listed in the application with regards to HbA1C as a diagnostic 
test. With HbA1C having the ability to diagnose and assess the 
severity in one test, this enables the practitioner to initiate 
management on the confirmatory return visit, resulting 
in decreased costs as a result of fewer returned general 
practice consultations[18]. Long-term health costs would also 
decrease, with early detection enabling early management 
and reducing risk of developing complications[17]. The 
HbA1C test is also less time consuming than OGTT, and easier 
to tolerate orally. Although data available is limited, it is 
evident from the above study and the suggestions outlined 
in the Australian proposal, which may also be applicable to 
other countries in the region. Hence, HbA1C should without 
doubt be considered a cost beneficial intervention in the 
diagnosis of T2DM.  
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2.6. Limitations to the use of HbA1C as a diagnostic and 
monitoring tool 
   As with many clinical tools, there are various genetic, 
hematologic and illness related factors as well as laboratory 
variances that can influence HbA1C results. Therefore, 
they are important to be conscious of during analysis and 
when determining its potential role in the diagnosis and 
management of T2DM. Studies have demonstrated that the 
intra-individual variance of HbA1C in patients without DM 
is minimal, less than 1%[4]. However, there is variance 
among individuals and this can be attributed to genetic 
related factors, age and the environment. Studies involving 
twins with T1DM suggest a strong genetic influence[3]. 
Approximately 33% of an inherited variance is said to be 
related to a “glycation gap”, which is the difference between 
the predicted HbA1C and the actual HbA1C[4]. This can be 
influenced by differences in erythrocyte transmembrane 
gradient, which will vary the degree of glucose entry into 
the erythrocyte, as well as diphosphoglycerate and pH 
levels within the cell[10]. A large amount of evidence is also 
surfacing to support the idea that race may perhaps affect 
levels of HbA1C[4,7]. Various studies have reported significant 
differences in HbA1C concentrations among different racial 
groups after adjusting for factors likely to influence glycemia. 
One study by Tsugawa et al. illustrated that Mexican 
Americans and African Americans had higher average 
HbA1C values compared to white Americans[19]. All this 
said however, remains unclear whether these reports have 
clinical significance, and perhaps, as authors speculated, a 
delay in diagnosis is the reason for different levels of HbA1C 
between “black” and “white” Americans[19,20]. Given the 
current variation in HbA1C concentrations is less than or equal 
to 0.4%, no consensus has been reached regarding different 
cutoffs of HbA1C for different racial groups[4]. Hematological 
and other illness related factors, particularly those that alter 
the normal life span of erythrocytes, such as splenomegaly, 
rheumatoid arthritis, acute blood loss, iron deficiency 
anemia and chronic alcoholism, could substantially alter 
the level of HbA1C, providing an inaccurate estimation of 
blood glucose control[10]. An important analytical factor to 
keep in mind is the clinical variances between laboratories 
and within laboratories given there are over 100 different 
methods of measurement[3]. With standardization being a 
major priority in Australia, further improvements are soon 
to be achieved following a national whole blood external 
quality control program developed by the Royal College of 
Pathologists of Australia and the Australian Association of 
Clinical Biochemists[4]. 
3. Conclusion
   In conclusion, given 7.5% of the Asia Pacific population 
aged 25 years and older have T2DM and for every person 
diagnosed or undiagnosed, the role of HbA1C and its 
possible value in diagnosing this chronic disease earlier 
is a worthwhile topic to have discussed[2]. With most 
undiagnosed diabetic patients having recognizable 
risk factors and 90% of these attending their general 
practitioner each year, it is apparent that a more simple 
and efficient diagnostic test is long overdue[15]. Not only 
have studies illustrated the importance of early diagnosis 
and immediate effective management to reduce the risk of 
developing the detrimental sequelae, but they have found 
that more effective glycemic control early results in long 
term benefits even if control eventually deteriorates[3]. 
Unlike America, where diagnostic use of HbA1C in T2DM 
has already been established, Asia Pacific countries have 
largely yet to completely recognize and implement such a 
convenient, accurate and opportunistic way of sampling. 
Until then, HbA1C remains only to be a form of glucose 
control monitoring in those already diagnosed. The longer 
the delay, the more likely those populations at high risk 
of T2DM in the region continuing to remain undiagnosed. 
Without regarding to food ingestion in sampling, it makes 
it more likely that HbA1C will result in detection of millions 
undiagnosed, making it a cost effective initiative as 
discussed above. Despite the limitations resulting in HbA1C 
not being an appropriate test to confirm diagnosis in those 
with a chronic medical disease, or who have anemia or 
another abnormality to their erythrocytes, HbA1C can be 
measured accurately in the vast majority of people[7,11]. 
Hence overall, HbA1C is a clinical tool whose use needs to 
be extended from simply monitoring glucose control to the 
diagnosis of T2DM in order to achieve improved outcomes 
and ultimately major long term health and cost benefits for 
the Asia Pacific region. 
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Comments 
Background
   Diabetes is a significant emergent disease in the Asia 
Pacific region that requires accurate and timely diagnosis 
to ensure effective and uniform management. The HbA1C test 
is now well recognized internationally as an appropriate 
diagnostic test. The paper examines the appropriateness of 
widely adopting this test for use in the Asia Pacific region.
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Research frontiers
   This paper has the potential to catalyse the widespread 
introduction of HbA1C testing for diabetes diagnosis 
throughout the Asia Pacific region. The authors have 
comprehensively researched the auguments for its 
introduction and have presented these in a clear and 
compelling form.   
Related reports
   Prevalence studies of diabetes in China have recently been 
published by Yang et al. It is estimated that over 150 million 
diabetics reside in the Asia Pacific region with over 95% 
being T2DM. Other papers cited validate the use of HbA1C as a 
diagnostic tool and include the advantages over the current 
methods and known limitations of the test. 
Innovations and breakthroughs
   This is a novel paper in its approach in that it builds a 
well-researched and evidenced rationale for the introduction 
of HbA1C testing as a diagnostic screening tool for diabetes in 
the Asia Pacific region.  
  
Applications
   With the growing and significant number of diabetes cases 
in the Asia Pacific region, a proven cost effective screening 
methodology to manage this public health epidemic is 
required. This paper provides a strong evidence based 
approach to suggest an appropriate rationale.
Peer review
   This is a well-researched and presented paper that 
will be especially helpful to clinicians and public health 
administrators tasked with implementing and managing 
regimes to treat the growing number of diabetic patients 
along with problems associated with their comorbidities.   
References
[1]    Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men 
and women in China. N Engl J Med 2010; 362(25): 2425-2426.
[2]    Routley VM. The emerging epidemic of type 2 diabetes –an Asian 
Pacific perspective. On The Risk 2011; 27(3): 72-76.
[3]    Hilton DJ, O’Rourke PK, Welborn TA, Reid CM. Diabetes 
detection in Australian general practice: a comparison of 
diagnostic criteria. Med J Aust 2002; 176(3): 104-107. 
[4]    d’Emden MC, Shaw JE, Colman PG, Colagiuri S, Twigg SM, Jones 
GR, et al. The role of HbA1C in the diagnosis of diabetes mellitus 
in Australia. Med J Aust 2012; 197(4): 220-221.
[5]    Kirkman MS, Kendall DM. Hemoglobin A1C to diagnose diabetes: 
why the controversy over adding a new tool? Clin Chem 2011; 
57(2): 255-257. 
[6]    Consensus Committee. Consensus statement on the worldwide 
standardization of the hemoglobin A1C measurement: the 
American Diabetes Association, European Association for the 
Study of Diabetes, International Federation of Clinical Chemistry 
and Laboratory Medicine, and the International Diabetes 
Federation. Diabetes Care 2007; 30(9): 2399-2400. 
[7]    Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin 
Standardization Program (NGSP) Steering Committee. Status of 
hemoglobin A1C measurement and goals for improvement: from 
chaos to order for improving diabetes care. Clin Chem 2011; 57(2): 
205-214.
[8]    Diabetes Australia. Diabetes management in general practice: 
guidelines for type 2 diabetes. Canberra: Diabetes Australia; 
2012. [Online] Available from: http://www.diabetesaustralia.
com.au/Documents/DA/What’s%20New/12.10.02%20Diabetes%20
Management%20in%20General%20Practice.pdf. [Accessed on 22nd 
October, 2013]
[9]    Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual 
hemoglobin in patients with diabetes mellitus. Biochem Biophys 
Res Commun 1969; 36(5): 838-843. 
[10]  Gallagher EJ, Roith DL, Bloomgarden Z. Review of hemoglobin 
A1C in the management of diabetes. J Diabetes 2009; 1(1): 9-17.
[11]  Sacks DB. A1C verses glucose testing: a comparison. Diabetes 
Care 2011; 34(2): 518-523.
[12]  Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross 
GP, et al. Position statement of the Australian Diabetes Society: 
individualization of glycated hemoglobin targets for adults with 
diabetes mellitus. Med J Aust 2009; 191(6): 339-344. 
[13]  Florkowski C, Crooke M. Standardisation of reporting hemoglobin 
A1C: adoption of the New Zealand Society for the Study of 
Diabetes (NZSSD) position statement. N Z Med J 2010; 123(1310): 
43-49.
[14]  World Health Organisation. HbA1C in the diagnosis of type 2 
diabetes: a systematic review. Geneva: World Health Organisation; 
2006. [Online] Available from: http://www.who.int/diabetes/
publications/sys_rev_hba1c_web.pdf. [Accessed on 22nd October, 
2013]
[15]  Peng G, Lin M, Zhang K, Chen J, Wang Y, Yang Y, et al. 
Hemoglobin A1C can identify more cardiovascular and metabolic 
risk profile in OGTT-negative Chinese population. Int J Med Sci 
2013; 10(8): 1028-1034. 
[16]  Martin DD, Shephard MD, Freeman H, Bulsara MK, Jones TW, 
Davis EA, et al. Point-of-care testing of HbA1C and blood glucose 
in a remote Aboriginal Australian community. Med J Aust 2005; 
182(10): 524-527.
[17]  Icks A, Haastert B, Gandjour A, John J, Löwel H, Holle R, et al. 
Cost-effectiveness analysis of different screening procedures for 
type 2 diabetes. Diabetes Care 2004; 27(9): 2120-2128.
[18]  Ryan K. HbA1C best option for diabetes diagnosis. Med J Aust 
2012; 197: 220-221. 
[19]  Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should 
the hemoglobin A(1C) diagnostic cutoff differ between blacks and 
whites?: a cross-sectional study. Ann Intern Med 2012; 157(3): 
153-159. 
[20] Kirk JK, Bell RA, Bertoni AG, Arcury TA, Quandt SA, Goff DC 
Jr, et al. Ethnic disparities: control of glycemia, blood pressure, 
and LDL cholesterol among US adults with type 2 diabetes. Ann 
Pharmacother 2005; 39(9): 1489-1501.
